{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:08:23Z","timestamp":1789715303134,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.pathol.2018.05.002","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T01:10:09Z","timestamp":1534986609000},"page":"635-641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications"],"prefix":"10.1016","volume":"50","author":[{"given":"Fabien","family":"Forest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Patoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dal Col","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-004X","authenticated-orcid":false,"given":"Abdulrazzaq","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Camy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bayle-Bleuez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3884-6816","authenticated-orcid":false,"given":"Pierre","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Habougit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2018.05.002_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00428-017-2109-z","article-title":"Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies","volume":"470","author":"Habougit","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2018.05.002_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A\u00a0nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2018.05.002_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2018.05.002_bib6","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2018.05.002_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2018.05.002_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.annpat.2014.01.009","article-title":"The French mesothelioma network from 1998 to 2013","volume":"34","author":"Galateau-Sall\u00e9","year":"2014","journal-title":"Ann Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.humpath.2016.10.005","article-title":"Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer","volume":"60","author":"Owen","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.pathol.2016.03.005","article-title":"Loss of expression of BAP1 is very rare in non-small cell lung carcinoma","volume":"48","author":"Andrici","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2018.05.002_bib11","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2018.05.002_bib12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","article-title":"BAP1 is altered by copy number loss, mutation, and\/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas","volume":"12","author":"Leblay","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2018.05.002_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.pathol.2018.05.002_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.13392","article-title":"The epithelioid, BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma","volume":"72","author":"Chou","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2018.05.002_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/0008-5472.CAN-15-0751","article-title":"Gender-specific molecular and clinical features underlie malignant pleural mesothelioma","volume":"76","author":"De Rienzo","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2018.05.002_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2018.05.002_bib17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?","author":"Pulford","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.pathol.2018.05.002_bib19","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/modpathol.2015.87","article-title":"Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology","volume":"28","author":"Andrici","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.annpat.2016.01.005","article-title":"BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: a comparative cytological and histological analyses on 50 patients","volume":"36","author":"Jaouen","year":"2016","journal-title":"Ann Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 Immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A\u00a0novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2018.05.002_bib24","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2018.05.002_bib25","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2018.05.002_bib26","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2018.05.002_bib27","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1038\/srep09928","article-title":"New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma","volume":"215","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2018.05.002_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186137","article-title":"Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models","volume":"12","author":"Alfaleh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2018.05.002_bib29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2018.05.002_bib30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2018.05.002_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2018.05.002_bib32","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2018.05.002_bib33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2018.05.002_bib34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21037\/tlcr.2017.06.01","article-title":"Novel systemic therapy against malignant pleural mesothelioma","volume":"6","author":"Mancuso","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.pathol.2018.05.002_bib35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302518300758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302518300758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T21:21:27Z","timestamp":1654636887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302518300758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0031302518300758"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2018.05.002","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2018.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}